Chugai Obtains Exclusive Commercialization Rights for Anamorelin in Europe from Helsinn

November 14, 2013
Chugai Pharmaceutical and Swiss-based drug maker Helsinn Group announced on November 12 that the two companies have entered into a license agreement for Helsinn’s investigational drug anamorelin, an oral, once daily ghrelin receptor agonist. With the agreement, Chugai Pharma Marketing,...read more